ADP Research will now be releasing data on a weekly basis, in addition to its monthly report, to provide high-frequency insights into the labor market.
Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal has not yet been reached.
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, prevention and portfolio structure are no longer guaranteed.
The AICPA announced the roll out of its own generative AI research tool, dubbed Josi, developed to provide secure, direct access to the AICPA’s professional standards, authoritative guidance and related information.
The IRS and the Treasury are proposing to remove the domestic corporation look-through rule for real estate investment trusts controlled by foreign investors.